Vimian Group AB (publ) (VIMGF)
USD 3.62
(0.0%)
USD 3.62
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 331.73 Million EUR | 31.52% |
| 2022 | 285.72 Million USD | 47.54% |
| 2021 | 193.66 Million USD | 112.8% |
| 2020 | 91 Million USD | 227.98% |
| 2019 | 27.74 Million USD | 195.77% |
| 2018 | 9.38 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 87.64 Million USD | -3.68% |
| 2024 Q2 | 98.32 Million USD | -0.34% |
| 2024 Q1 | 91.29 Million EUR | 10.72% |
| 2023 FY | 375.77 Million USD | 31.52% |
| 2023 Q2 | 86.1 Million USD | -9.0% |
| 2023 Q1 | 94.61 Million USD | 20.02% |
| 2023 Q3 | 85.68 Million USD | -0.49% |
| 2023 Q4 | 93.36 Million USD | 8.97% |
| 2022 Q3 | 67.53 Million USD | -1.31% |
| 2022 FY | 285.72 Million USD | 47.54% |
| 2022 Q4 | 78.83 Million USD | 16.73% |
| 2022 Q2 | 68.43 Million EUR | -9.5% |
| 2022 Q1 | 75.61 Million EUR | 39.21% |
| 2021 FY | 193.66 Million USD | 112.8% |
| 2021 Q3 | 48.12 Million EUR | 2.89% |
| 2021 Q4 | 54.31 Million EUR | 12.87% |
| 2021 Q2 | 46.77 Million EUR | -7.88% |
| 2021 Q1 | 50.77 Million EUR | -46.25% |
| 2020 Q4 | 94.45 Million EUR | 354.12% |
| 2020 FY | 91 Million USD | 227.98% |
| 2020 Q2 | 11.97 Million EUR | 13.78% |
| 2020 Q1 | 10.52 Million EUR | 0.0% |
| 2020 Q3 | 20.79 Million EUR | 73.69% |
| 2019 FY | 27.74 Million USD | 195.77% |
| 2018 FY | 9.38 Million EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | -36234.064% |
| Arrayit Corporation | 4.37 Million USD | -7478.416% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | -1182.891% |
| Bioqual, Inc. | 58.59 Million USD | -466.18% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | -2068.737% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 95.507% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | -5110.784% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | -31445.564% |
| Interpace Biosciences, Inc. | 40.21 Million USD | -724.912% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | -74029.775% |
| InVitro International | 792.62 Thousand USD | -41751.915% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | -2880.235% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | -4491.911% |
| NovelStem International Corp. | 12 Thousand USD | -2764316.667% |
| Optigenex Inc. | 465.97 Thousand USD | -71091.278% |
| PharmChem, Inc. | 6.01 Million USD | -5417.428% |
| Proteome Sciences plc | 6.4 Million USD | -5082.76% |
| Response Genetics, Inc | 18.04 Million USD | -1738.858% |
| Rennova Health, Inc. | 13.03 Million USD | -2444.689% |
| RushNet, Inc. | 1.78 Million USD | -18454.377% |
| ScreenPro Security Inc. | 1.91 Million USD | -17230.833% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | -8641.063% |
| Todos Medical Ltd. | 7.69 Million USD | -4210.981% |